Related Experiment Video
Updated: Feb 2, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elena Elez1, Carlos Gomez-Roca2, Arturo Soto Matos-Pita3
1Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Abstract:
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated dose-limiting toxicities (DLT) to define the maximum tolerated dose (MTD) and phase II recommended dose (RD) of plocabulin given as a 10-min infusion on Day (D) 1, D8 and D15 every four weeks. Patients and methods Forty-four patients with advanced solid tumors received plocabulin following an accelerated titration design. Results Plocabulin was escalated from 1.3 mg/m2 to 14.5 mg/m2, which was defined as the MTD. No RD was confirmed, because frequent dose delays and omissions resulted in low relative dose intensity (66%) at the 12.0 mg/m2 expansion cohort. The main DLT was grade 3 peripheral sensory neuropathy (PSN); other DLTs were grade 4 tumor lysis syndrome, grade 4 cardiac failure and grade 3 myalgia. Toxicities were mainly mild to moderate, and included abdominal pain, myalgia, fatigue, nausea, and vomiting. Myelosuppression was transient and manageable. Plocabulin had a half-life of ~4 h and a wide diffusion to peripheral tissues. Antitumor response was observed in cervix carcinoma and heavily pretreated metastatic non-small cell lung cancer patients, and disease stabilization (≥3 months) in patients with colorectal, thymic, gastrointestinal stromal and breast tumors, among others. The clinical benefit rate was 33%. Conclusion The main DLT of plocabulin was PSN, as anticipated for a tubulin-binding agent. Since encouraging antitumor activity was observed, efforts to improve toxicity and to find the RD were planned in other trials evaluating D1&D8 and D1-D3 plus D15-D17 schedules.
Insights
Plocabulin, a novel marine-derived microtubule inhibitor, showed antitumor activity in advanced solid tumors. Peripheral sensory neuropathy was the main dose-limiting toxicity, necessitating further trials to optimize its use.
Area of Science:
- Oncology
- Pharmacology
- Marine Biotechnology
Background:
- Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor with antitumor properties.
- This study assessed dose-limiting toxicities (DLT) to establish the maximum tolerated dose (MTD) and phase II recommended dose (RD) of plocabulin.
Purpose of the Study:
- To determine the MTD and RD of plocabulin in patients with advanced solid tumors.
- To evaluate the safety and preliminary efficacy of plocabulin administered via infusion.
Main Methods:
- Forty-four patients with advanced solid tumors received plocabulin using an accelerated titration design.
- Plocabulin was administered as a 10-min infusion on Days 1, 8, and 15 every four weeks.
- Dose escalation ranged from 1.3 mg/m² to 14.5 mg/m².
Main Results:
- The MTD was determined to be 14.5 mg/m².
- A recommended dose (RD) was not confirmed due to dose delays and omissions, resulting in low relative dose intensity (66%) at 12.0 mg/m².
- The primary dose-limiting toxicity was grade 3 peripheral sensory neuropathy (PSN); other DLTs included tumor lysis syndrome, cardiac failure, and myalgia. Transient and manageable myelosuppression was observed.
- Antitumor responses and disease stabilization were noted in various advanced solid tumors, with a 33% clinical benefit rate.
Conclusions:
- Peripheral sensory neuropathy is the primary dose-limiting toxicity for plocabulin, consistent with its mechanism as a tubulin-binding agent.
- Encouraging antitumor activity warrants further investigation with modified dosing schedules (e.g., D1&D8, D1-3 & D15-17) to optimize toxicity and identify the RD.
More Related Videos
Related Concept Videos
Microtubules
Microtubules
Microtubules have two structurally similar globular protein subunits: α and β tubulins. In the cytosol, the α and β tubulins form a heterodimer....
Phase Diagrams
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Phase Transitions

